结合影像学与体格检查分期的CAPRA评分预后评估稳定性
研究纳入2000至2019年接受根治性前列腺切除术、直肠指检与影像学分期均≤cT3a的前列腺癌患者2222例,比较基于直肠指检与基于影像学T分期计算的CAPRA评分对生化复发的预测效能。结果显示两种方法预测准确性相当,影像学分期可使部分患者CAPRA评分升高,但判别力与决策曲线分析相似。
要点
- 2222例中377例(17%)因影像学分期导致CAPRA评分升高(P < .01)。
- 基于直肠指检的CAPRA评分预测复发HR 1.54(95% CI 1.48-1.61),基于影像学的HR 1.52(95% CI 1.46-1.58),准确性相当。
- 直肠指检阳性(HR 1.29;95% CI 1.09-1.53)与影像学临床T3/4期(HR 1.72;95% CI 1.43-2.07)均独立与生化复发相关。
核心结论
- CAPRA评分无论采用影像学分期还是直肠指检分期计算均保持准确,两者与生化复发的关联相似,差异较小。
- 来自任一模式的 stagging 信息均可用于CAPRA评分计算,并仍能可靠预测生化复发风险。
研究设计与样本
- 回顾性纳入2000至2019年诊断为前列腺癌并接受根治性前列腺切除术、直肠指检与影像学(经直肠超声/MRI)分期均≤cT3a的患者2222例。
- 分别以直肠指检T分期和影像学T分期计算加州大学旧金山分校CAPRA评分,比较两种方法间的风险变化及与生化复发的关联。
- 采用未校正和校正Cox比例风险模型分析关联,并以时间依赖AUC和决策曲线分析评估模型判别力与净获益。
主要发现
- 2222例中377例(17%)因采用影像学分期而使CAPRA评分升高(P < .01)。
- 基于直肠指检的CAPRA评分预测复发HR 1.54(95% CI 1.48-1.61),基于影像学的CAPRA评分HR 1.52(95% CI 1.46-1.58),两者判别力与决策曲线分析相似。
- 多变量Cox回归中,诊断时直肠指检阳性(HR 1.29;95% CI 1.09-1.53)与影像学临床T3/4期疾病(HR 1.72;95% CI 1.43-2.07)均独立与生化复发相关。
临床怎么用
- 作者认为,来自影像学或直肠指检的 stagging 信息均可用于CAPRA评分计算,并仍能可靠预测生化复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although official T-staging criteria for prostate cancer are based on digital rectal examination findings, providers increasingly rely on transrectal US and MRI to define pragmatic clinical stage to guide management. We assessed the impact of incorporating imaging findings into T-staging on performance of a well-validated prognostic instrument. MATERIALS AND METHODS: Patients who underwent radical prostatectomy for prostate cancer diagnosed between 2000 and 2019 with stage ≤cT3a on both digital rectal examination and imaging (transrectal US/MRI) were included. The University of California, San Francisco CAPRA (Cancer of the Prostate Risk Assessment) score was computed 2 ways: (1) incorporating digital rectal examination-based T stage and (2) incorporating imaging-based T stage. We assessed for risk changes across the 2 methods and associations of CAPRA (by both methods) with biochemical recurrence, using unadjusted and adjusted Cox proportional hazards models. Model discrimination and net benefit were assessed with time-dependent area under the curve and decision curve analysis, respectively. RESULTS: Of 2,222 men included, 377 (17%) increased in CAPRA score with imaging-based staging (P < .01). Digital rectal examination-based (HR 1.54; 95% CI 1.48-1.61) and imaging-based (HR 1.52; 95% CI 1.46-1.58) CAPRA scores were comparably accurate for predicting recurrence with similar discrimination and decision curve analyses. On multivariable Cox regression, positive digital rectal examination at diagnosis (HR 1.29; 95% CI 1.09-1.53) and imaging-based clinical T3/4 disease (HR 1.72; 95% CI 1.43-2.07) were independently associated with biochemical recurrence. CONCLUSIONS: The CAPRA score remains accurate whether determined using imaging-based staging or digital rectal examination-based staging, with relatively minor discrepancies and similar associations with biochemical recurrence. Staging information from either modality can be used in the CAPRA score calculation and still reliably predict risk of biochemical recurrence.
引用
- Chang K, Greenberg SA, Cowan JE, et al. Stability of Prognostic Estimation Using the CAPRA Score Incorporating Imaging-based vs Physical Exam-based Staging. J Urol. 2023. PMID: 37099018. doi:10.1097/JU.0000000000003486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。